Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults

OBJECTIVES: We investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of evacetrapib. METHODS: Healthy volunteers received multiple daily doses of evacetrapib (10–600 mg) administered for up to 15 days in a placebo-controlled study. KEY FINDINGS: Mean peak plasma concentrations...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Pharm Pharmacol
Main Authors: Suico, Jeffrey G, Wang, Ming-Dauh, Friedrich, Stuart, Cannady, Ellen A, Konkoy, Christopher S, Ruotolo, Giacomo, Krueger, Kathryn A
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Ltd 2014
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4284021/
https://ncbi.nlm.nih.gov/pubmed/24961753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jphp.12287
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados